Final height and weight of long-term survivors of childhood malignancies

2009 ◽  
Vol 106 (02) ◽  
pp. 135-139 ◽  
Author(s):  
H. L. Müller ◽  
M. Klinkhammer-Schalke ◽  
J. Kühl
1994 ◽  
Vol 153 (10) ◽  
pp. 726-730 ◽  
Author(s):  
A. Cicognani ◽  
E. Cacciari ◽  
P. Rosito ◽  
A. F. Mancini ◽  
G. Carlă ◽  
...  

2018 ◽  
Vol 27 (5) ◽  
pp. 1891-1899
Author(s):  
Deniz Çetiner ◽  
Sedat Çetiner ◽  
Ahu Uraz ◽  
Gökhan H. Alpaslan ◽  
Cansu Alpaslan ◽  
...  

1982 ◽  
Vol 6 (1) ◽  
pp. 223
Author(s):  
J. C. Allen ◽  
M. D. F. Deck ◽  
J. Howieson ◽  
M. Brown

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii381-iii381
Author(s):  
Martin Harutyunyan ◽  
Lilit Sargsyan ◽  
Samvel Iskanyan ◽  
Lusine Hakobyan ◽  
Ruzanna Papyan ◽  
...  

Abstract BACKGROUND Pediatric CNS tumors are the most common solid childhood malignancies with many challenges facing optimal outcome due to multimodality complex therapies, abandonment, and long-term morbidity. In our three-decades young, country the field of neuro-oncology is in its infancy. MATERIALS: The aim of our study is to assess incidence, epidemiology and treatment outcomes of children diagnosed and treated with CNS tumors within the last 10 years (2009–2019) in the Chemotherapy Clinic of “Muratsan” Hospital Complex of Yerevan State Medical University. RESULTS During these periods 20 patients with CNS tumors were treated in our clinic. 13 patients (65%) were diagnosed with medulloblastoma (2 patients were infants), two patients (10%) with optic pathway glioma, and 5 patients each with pilocytic astrocytoma, ATRT, ETANTR, DIPG, and glioblastoma. Five patients (3 patients with medulloblastoma, 1 patient with pilocytic astrocytoma, 1 patient with ATRT) had metastatic disease at the time of diagnosis. Seventeen patients (80%) had undergone surgery, 8 patients with medulloblastoma received chemo-RT with vincristine. Median follow up time was 15.5 months (range 5–94). Twelve patients (60%) are alive without evidence of disease. 5 patients had disease progression and three patients relapsed. From them, 3 patients died. Long-term survivors are mainly standard risk medulloblastoma patients. All medulloblastoma patients were treated according to HIT-MED guidelines. CONCLUSION Here we report about the pediatric brain tumors of one of the main pediatric oncology units in Armenia for a period of 10 years. The numbers are quite small for firm conclusions, but it shows the emerging need for further research.


1981 ◽  
Vol 9 (2) ◽  
pp. 109-117 ◽  
Author(s):  
Jeffrey C. Allen ◽  
Michael D. F. Deck ◽  
John Howieson ◽  
Mark Brown

1992 ◽  
Vol 10 (1) ◽  
pp. 128-133 ◽  
Author(s):  
M J Schell ◽  
J J Ochs ◽  
E A Schriock ◽  
M Carter

PURPOSE Short stature and obesity have been reported among long-term survivors of childhood acute lymphocytic leukemia (ALL). We examined factors that contribute to these adverse sequelae. PATIENTS AND METHODS Serial height and weight measurements were analyzed for 91 long-term survivors who were treated for ALL between 1967 and 1975 at a single institution. These patients were all younger than 12 years at diagnosis, were in continuous complete remission, had reached final height, and had height and weight measurements within 1 year of age 18 years. They had received craniospinal (n = 33) or cranial irradiation (n = 58) to total doses of 24 Gy as CNS prophylaxis. Standard deviation scores (SDS) were used to reflect the deviation of height and weight measurements from population means, and the body mass index (BMI; weight divided by height squared) was used in assessing obesity at age 18 years. RESULTS Short stature (less than fifth percentile) was seen in 41 patients (45%), and obesity (BMI greater than or equal to 24 kg/m2) in 35 (38%). Regression formulae were developed that explain 65% and 62% of the variability in patient height and BMI, respectively. CONCLUSIONS Risk factors were identified for abnormally short stature, which was defined to be a decrease of 1.5 SDS in height from diagnosis to age 18 years. These factors include younger age and above-average height for age at diagnosis (height SDS greater than 0), craniospinal irradiation, and greater decrease in height SDS during antileukemic therapy. Risk factors for obesity at age 18 years include weight SDS greater than 0 and greater than height SDS at 1 year after the end of chemotherapy.


Sign in / Sign up

Export Citation Format

Share Document